Dihydroartemisinin increases gemcitabine therapeutic efficacy in ovarian cancer by inducing reactive oxygen species
1 | INTRODUCTION
Human ovarian carcinoma is the leading cause of death from gynecological malignancy and the fifth among common cancer death.1,2 Most women with ovarian carcinoma were diagnosed at advanced stages and the 5‐year survival for the patients has remained unchanged (<20%) over the past 20 years. It is still a challenge for the treatment of ovarian carcinoma.
Gemcitabine ([GEM]; 2′,2′‐difluorodeoxycytidine [dFdC]) is commonly used in chemotherapy for ovarian cancer, non–small‐cell lung cancer, breast cancer, and pancreatic cancer.3-5 GEM is a prodrug, after entering the cells, it can be phosphorylated stepwise by deoxycytidine kinase (dCK) into active 2′,2′‐difluorodeoxycytidine triphosphate (dFdCTP) metabolite.6-8 However, GEM is a pyrimidine nucleoside analogue of deoxycytidine and can be catalyzed to 2′‐deoxy‐2′,2′‐difluorouridine (dFdU), an inactive metabolite of GEM, by stromal and CDA.9,10
Indeed, it is reported that more than 90% GEM is inactivated into dFdU before dFdCTP incorporated into DNA strands to inhibit DNA replication and promote apoptosis in cancer cells.10 Therefore, the interference of CDA expression in cancer cells could decrease GEM inactivation, leading to increased drug uptake at the tumor site.
Artemisiae annuae Herba was initially used for treating fevers and then renowned to be an antimalarial herb,11,12 in which the most important active ingredient is artemisinin. Artemisinin was discovered and developed by Tu Youyou, for which she was awarded the 2015 Nobel Prize in Physiology or Medicine. Recent studies indicated that artemisinin showed high potential antitumor properties.13 Dihydroartemisinin (DHA) is one of important derivatives of artemisinin and also exhibits potent antimalarial ability and antitumor potential.14-17 Artemisinin and DHA possess an unusual intramolecular endoperoxide bridge and the endoperoxide bond can be activated by heme or ferrous iron to produce the cytotoxic reactive oxygen species (ROS).18-21 DHA can induce cancer cell apoptosis by producing excess ROS to cause oxidative damage to proteins, DNA, or lipids.22-24 It was reported that the higher oxidative stress could induce excess expression of heme oxygenase‐1 (HO‐1), which could further suppress cytidine deaminase (CDA) expression in cancer cells.25,26
Herein, we report the synergistic effect of DHA + GEM on antitumor efficiency. We hypothesized that DHA could induce excess ROS generation, then the higher oxidative stress could induce excess expression of HO‐1, which could suppress CDA expression and decrease the GEM inactivation
in turn. Specifically, we take advantage of the DHA + GEM combination for the treatment of ovarian carcinoma A2780. The ROS generation by DHA was monitored by flow cytometry and confocal laser scanning microscopy (CLSM), meanwhile the cytotoxicity assay of DHA was conducted in vitro. In addition, the synergistic effect of DHA + GEM was verified in vitro and in vivo.
2 | MATERIALS AND METHODS
2.1 | Materials
DHA (Energy chemical, Shanghai, China), Cremophor EL (Aladdin, Shanghai, China), N‐acetyl cysteine (NAC; Aladdin, Shanghai, China), 2′,7′‐dichlorodihydrofluorescein diacetate (DCF‐DA; Aladdin, Shanghai, China), gemcitabine hydrochloride (GEM; Yangzhou Huihong Chemical Co. Ltd., Yangzhou, China) and 3‐(4,5‐dimethyl‐thiazol‐2‐yl)‐ 2,5‐diphenyl tetrazolium bromide (MTT; Sigma‐Aldrich, Shanghai, China), and Hoechst 33258 (Sigma‐Aldrich,
Shanghai, China) were used as received without further purification. All the other reagents were purchased from the Sinopharm Chemical Reagent Co. Ltd (Beijing, China) and used as received.
2.2 | Cell culture
Human ovarian cancer cell lines (A2780) and murine fibroblast cell lines (L929) were purchased from Shanghai Bogoo Biotechnology Co. Ltd (Shanghai, China). The cells were cultured in Dulbecco modified Eagle medium (DMEM; Gibco, Grand Island, NY) with high glucose containing 10% fetal bovine serum (FBS), supplemented with 1% penicillin and 1% streptomycin incubating at 37° C in a 5% CO2 atmosphere.
2.3 | Measurement of ROS generation
The generation of ROS induced by DHA was monitored by flow cytometry and CLSM with an oxidation‐sensitive probe 2′,7′‐dichlorodihydrofluorescein diacetate (DCF‐DA). The DCF‐DA can be cleaved by nonspecific esterases and becomes highly fluorescent DCF upon oxidation by ROS. For the flow cytometry assay, 4 × 105 A2780 or L929 cells per well were seeded in the six‐well plates and incubated overnight with 2 mL DMEM, and then replaced
with fresh DMEM containing DHA with or without NAC (10 mM). After 24 hours, the cells were washed with 3 mL phosphate‐buffered saline (PBS) for three times, and incubated with DMEM containing DCF‐DA (5 μM) for 1 hour at 37°C. Then the cells were washed with PBS for three times and treated by trypsin without EDTA and collected in 1 mL PBS. The cell suspension was centrifuged at 500g for 5 minutes and washed twice with 1 mL PBS. Eventually, the cells were suspended in 0.3 mL PBS for flow cytometry tests (BD Biosciences, San Jose, CA).
For the CLSM assay, 4 × 105 A2780 cells per well were seeded onto glass coverslips placed in the six‐well plates and incubated overnight for cell adherence culture, then replaced with fresh DMEM with (a) DHA (50 μM), (b) DHA (100 μM), (c) DHA (100 μM) + NAC (10 mM), or (d) DHA (100 μM) + FeSO4 (10 mM). After 24 hours, the cells were washed with 3 mL PBS for three times and incubated with DMEM containing DCF‐DA (100 μM) for 1 hour at 37°C.
Then the cells were washed with PBS for three times and fixed with 4% formaldehyde for 20 minutes at room temperature, followed by washing the residual formalde- hyde with PBS for three times. According to the manufacturer’s instructions, the cell nuclei were stained with Hoechst 33258. The coverslips were placed onto glass microscope slides and fixed with nail polish, and the fluorescence of DCF was visualized using a CLSM (Carl Zeiss LSM 700, Carl Zeiss, Jena, Germany).
2.4 | DHA cellular cytotoxicity assay in vitro
To verify the DHA could induce the cellular cytotoxicity by generating ROS, the A2780 cells were seeded in the 96‐well plates with a density of 7000 cells per well and incubated overnight with 100 μL DMEM for cell adherence culture, then replaced with 200 μL fresh DMEM with different concentration of DHA or DHA + NAC. The cells were subjected to MTT assay after being incubated for another 48 hours. Specifically, at the end of
the experiments, 20 μL MTT (1 mg/mL in sterile PBS) was added into the 96‐well plates with 180 μL fresh DMEM for another 4 hours incubation. The supernatant was removed and 100 μL DMSO was added. The absorbance of the solution was measured on a Bio‐Rad 680 microplate reader (Bio‐Rad, Hercules, CA) at 490 nm. The relative cell viability (%) was calculated by the following formula: detection system (Tanon Science & Technology Co. Ltd., Shanghai, China).
2.6 | The effect of DHA on CDA expression
To investigate the influence of DHA on CDA expression, the immunocytochemistry (ICC) assay was conducted on A2780. The cells were seeded onto glass coverslips placed in the six‐well plates with a density of 1.5 × 105 cells per well and incubated overnight for cell adherence culture, following treated with PBS or 50 μM DHA for 24 hours.
2.5 | The effect of DHA on HO‐1 expression
To investigate the effect of DHA on HO‐1 expression, Western blot analysis was carried out with whole‐cell lysates. A2780 cells were treated with PBS or 50 μM DHA for 24 hours. Whole‐cell proteins were prepared by lysing the cells in RIPA Lysis Buffer supplemented with 1 mM proteinase inhibitor phenylmethanesulfonyl fluoride (PMSF) (Beyotime, Shanghai, China). After protein lysates were quantified, 40 μg of protein was loaded into 15% polyacrylamide sodium dodecyl sulfate‐polyacryla- mide gel electrophoresis (SDS‐PAGE) and electrophor- etically transferred to polyvinylidene difluoride (PVDF) membranes (Bio‐Rad). The membrane was blocked with Tris‐buffered saline plus 0.1% Tween 20 plus 5.0% skim milk. Then PVDF membrane was incubated overnight with primary antibody against HO‐1 (R&D Systems, Minneapolis, MN) at 4°C. Glyceraldehyde 3‐phosphate dehydrogenase was used as an internal reference. The membrane was then washed and incubated for 1 hour with a secondary antibody. The proteins were visualized using an enhanced chemiluminescence Western blot albumin for 1 hour to block nonspecific protein‐protein interactions. The cells were incubated with the primary antibody against CDA (Abcam, Cambridge, MA) over- night at 4°C. The secondary antibody was fluorescein‐5‐ isothiocyanate (FITC) conjugated goat anti‐rabbit immunoglobulin G (IgG) (H + L) (ABclonal, Wuhan, China) used at a 1/50 dilution for 2 hours. Hoechst 33258 was used to stain the cell nuclei. The coverslips were placed onto glass microscope slides and fixed with nail polish, and visualized using a CLSM system.
2.7 | The synergistic effect of DHA and GEM in vitro
To investigate the interaction with GEM, the in vitro cytotoxicities of DHA and GEM on A2780 were assessed by MTT and apoptosis assay.
For the MTT assay, A2780 cells were seeded in 96‐well plates at 5000 cells per well and incubated overnight with 100 μL DMEM for cell adherence culture, then replaced with 200 μL fresh DMEM with different concentration of DHA, GEM, or their combination. All the other procedures are similar to the above. The inhibitory concentration (ICx) values are determined using Origin 9.2 according to the fitted data. The combination index (CI) was measured according to the Chou and Talalay’s method.27 To distinguish synergistic, additive, or antagonistic cytotoxic effects, the following equation was used: where (Dx)a and (Dx)b represent the ICx value of drug 'a' alone and drug 'b' alone, respectively. (D)a and (D)b represent the concentration of drug 'a' and drug 'b' in the combination system at the ICx value. CI > 1 represents antagonism, CI = 1 represents additive, and CI < 1 represents synergism. In this study, IC50 (inhibitory concentration to produce 50% cell death) was applied.
Cell apoptosis detection was performed by flow cytometry (FCM) analysis using annexin V‐FITC apop- tosis detection kit (KeyGEN Biotech,Nanjing,China). Approximately 4 × 105 A2780 cells were seeded in six‐ well plates and treated with DHA, GEM, or their combination at specific concentrations for 48 hours before analysis. The floating and trypsinized adherent cells were collected and prepared for detection according to the manufacturer’s instructions. Samples were ana- lyzed with a FACS Aria flow cytometer (BD Biosciences).
2.8 | Animals
Female Balb/C nude mice (6–8 weeks old) were obtained from Beijing Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China). The mice were raised in specific pathogen‐free animal laboratory. All animals received care in compliance with the guidelines outlined in the Guide for the Care and Use of Laboratory Animals and all procedures were approved by the Animal Care and Use Committee of Jilin University.
2.9 | Antitumor efficiency in vivo
A2780 cells (5 × 106 per mouse) were subcutaneously injected into the right flank to obtain ovarian cancer xenograft tumor model. The mice were divided into four groups randomly when the tumors volume reached approximately 120 mm3. The four groups mice were treated with PBS (control), DHA (95 mg/kg), GEM (10 mg/kg), or DHA + GEM (DHA 95 mg/kg, GEM 10 mg/kg) and injected on days 0, 3, 6, and 9. DHA was dissolved in Cremophor EL:ethanol:saline (1:1:8, vol/vol/vol) and administered via intraperito- neal (ip) injections. GEM was dissolved in PBS and administered intravenously via the tail vein (i.v.). The antitumor activity was evaluated by the tumor volumes (Vt), which were calculated using the following equations. Meanwhile, the body weight was measured simultaneously each other day as a symbol of the systemic toxicity. At the end of the assay, mice were killed. The tumors and major organs (heart, liver, spleen, lung, and kidney) were excised for histopathol- ogy analyses:where a and b represented the longest and shortest diameter of the tumors measured by a vernier caliper, respectively.
FIGURE 1 Flow cytometric images of DHA‐induced ROS generation in A2780 and L929 cells with different DHA‐treated concentration (A,C) and the production of ROS was markedly inhibited by pretreating the cells with NAC (B,D). DHA, dihydroartemisinin; NAC, N‐acetyl cysteine; ROS, reactive oxygen species
2.10 | Blood biochemistry and blood routine examination
Whole blood was collected from healthy nude mice after four repeated treatments at day 14. Blood was collected in a sodium EDTA anticoagulant tube for the hematology study. Red blood cells (RBC), white blood cells (WBC), platelets (PLT), hemoglobin (HGB), and hematocrits (HCT) were counted for the detection of myelosup- pression.
2.11 | Histological and immunohistochemical analyses
The excised tumors and major organs were fixed in 4% PBS buffered paraformaldehyde overnight, and then embedded in paraffin. The paraffin‐embedded tumors and organs were cut at 5 μm thickness, and stained with hematoxylin and eosin (H&E) to assess histological alterations by optical microscope (Nikon TE2000U).
2.12 | Statistical analysis
All experiments were performed at least three times and expressed as means ± SD. Data were analyzed for statistical significance using the Student t test. P < 0.01 was considered extremely significant difference.
3 | RESULTS
3.1 | The measurement of ROS generation
The ROS were analyzed using nonfluorescent DCF‐DA, which could be activated into a green fluorescent product, DCF. The green fluorescent was measured by flow cytometer. As shown in Figure 1A, ROS was generated within A2780 cells treated with 25 μM DHA and the green fluorescent was greatly enhanced with the increase of treated DHA concentration. It was thus concluded that DHA could induce ROS generation inside cells. Addition of N‐acetyl cysteine (NAC), a ROS scavenger, could markedly decrease the green fluorescent (Figure 1B), proving the generation of ROS from another angle. Similar results were confirmed in fibroblast cell L929 (Figure 1C and 1D). Notably, the amount of inherent ROS generated in L929 was significantly lower compared with A2780 cancer cells, which indicates that the cancer cells were more vulnerable to the cytotoxic effects of DHA than normal cells.
Intracellular ROS generation was also detected by CLSM. As Figure 2 shows, the ROS was mainly produced in cytoplasm and ROS levels significantly increased in a concentration‐dependent manner, which displayed con- sistent results from FCM analysis (Figure 1). The antioxidant NAC could abrogate the green DCF fluores- cence, suggesting DHA treatment led to induction of ROS. The ROS generation by endoperoxide DHA was mediated by iron(II) heme. When adding additional ferrous ion (Fe(II)) (10 mM), the ROS generation was remarkably elevated, indicating that intramolecular endoperoxide bridge of DHA could be activated by ferrous iron to produce the cytotoxic ROS.
3.2 | DHA cellular cytotoxicity assay in vitro
The antitumor activity of DHA were conducted in A2780 cells. MTT assay manifested that DHA possessed a dose‐dependent anticancer capability in A2780 cell lines. The DHA could induce cytotoxicity by generating ROS.ROS generation (Figure 1 and 2). DHA is a sesquiterpene lactone with an endoperoxide and DHA can be activated by ferrous iron to produce ROS via endoperoxide cleavage.28 Moreover, the obvious cytotoxicity was observed when such extra ferrous ion was added into DHA (Figure 3B), indicating that DHA‐reduced intracellular ROS were essential for DHA to exert its cytotoxic activity.
3.3 | The effect of DHA on HO‐1 and CDA expression
DHA could induce intracellular ROS generation, simul- taneously, HO‐1, acted as a marker of oxidative stress, was performed by Western blot analysis. As shown in Figure 4A, DHA could significantly increase HO‐1 expression on A2780 cells compared with PBS after 24 hours treatment. In addition, we evaluated the effect of DHA on CDA expression using ICC experiments. The green fluorescence intensity of DHA‐treated cells was profoundly decreased (Figure 4B), indicating that DHA could downregulate the CDA expression.
3.4 | The synergistic effect of DHA and GEM in vitro
DHA could induce intracellular ROS generation to excite oxidative stress (HO‐1 expression), which suppressed CDA expression. The lower expression of CDA in cells contributed to inhibit GEM metabolic inactivation. A series of different combination treatment ratios were conducted by MTT assay to investigate distinct interac- tions, ranging from antagonism to synergism. The IC50 of the DHA and GEM on A2780 cells at 72 hours were 78.1
and 1.29 μM, respectively. The combination index (CI) were calculated using the Chou and Talalay’s method.
The CI values of different combination treatment ratios were summarized in Table 1. When the molar ratio of DHA and GEM was 10, strong synergism was observed, with CI values 0.7, while the other ratio of the two drugs had suboptimal synergistic effect. Overall, employing the optimal molar ratio (DHA/GEM, 10:1, mol/mol) ap- peared to be necessary for maximal augmentation of antitumor activity in A2780 human ovarian cancer cells. A2780 cells were treated with DHA, GEM, or their combination and cell apoptosis detection was conducted at 48 hours using annexin V‐FITC apoptosis detection kit.
The lower left quadrant (LL), upper left quadrant (UL), lower right quadrant (LR), and upper right quadrant (UR) represents live cells, fragments, and damage cells, early apoptosis, and late apoptosis cells, respectively. As shown in Figure 5, GEM could induce apoptotic rate for 39.6% and 25.7% of the cells in early apoptosis (LR) and in late apoptosis (UR), respectively. And the combination treatment group produced markedly more pronounced apoptosis than DHA or GEM alone treatment, the apoptotic of combination treatment were 54.5% (LR) and 37.0% (UR), respectively.
3.5 | Antitumor efficiency in vivo
Inspired by the pronounced antiproliferation effect of the DHA + GEM combination treatment in vitro, the anti- tumor efficiency of the DHA, GEM, or the DHA + GEM combination on A2780 ovarian cancer xenograft tumor model was conducted. When the tumors were about 120 mm3, mice received the treatment with PBS, DHA (ip), GEM (iv) or DHA + GEM combination on days 0, 3, 6, and 9. Tumor volumes and mice body weights were measured every other day. As Figure 6A shows, DHA‐treated group had inconspicuous therapeutic effects compared with control group and mice treated with GEM showed remarkable inhibition on tumor growth. While the DHA + GEM combination treatment group had unexpected antitumor efficiency, the tumors were completely eliminated on day 14 (Figure 6B). The changes of mice body weight were a symbol of systemic toxicity. As shown in Figure 6C, the three treated groups had no weight descends, indicating that the DHA + GEM combination treatment was worth taking.
3.6 | Blood biochemistry and blood routine examination
Since the major side effect of GEM was myelosuppres- sion, blood routine examination was conducted on day 14 (Figure 7). Owing to the lower treatment dose and reasonable treatment time design of DHA + GEM, the levels of platelets (PLT), white blood cells (WBC), red blood cells (RBC), hemoglobin (HGB), and hematocrit (HCT) were close to the value of the untreated control. However, the GEM alone treatment group has slight increase in the levels of PLT and WBC on day 14, while the DHA + GEM treatment group had no noticeable aggravation of blood toxicity.
3.7 | Histological and immunohistochemical analyses
The tumors and major organs were collected at the end of the antitumor experiments. Through histological analysis using H&E staining to tissue slices, the therapeutic effects of the DHA, GEM or DHA + GEM combination were assessed. Owing to the complete elimination of tumors of the DHA + GEM combination group, there was no representative H&E picture of the tumor. For the H&E staining, the tumor treated with PBS had large nuclei and more chromatin, revealing the powerful proliferation ability of tumor cell (Figure 8). The degrees of tumor tissue necrosis treated with DHA were unobvious, which was consistent with the antitumor efficiency. However, the overt tumor tissue necrosis was observed when mice were treated with GEM. In addition, there was no obvious necrosis or significant morphological changes of heart, liver, spleen, lung, and kidney derived from mice in treatment groups compared to control group.
4 | DISCUSSION
Compared with normal cells, cancer cells have higher levels of ROS and oxidative stress.29 And ROS could influence and regulate the expression of proteins in signal transduction pathways.30 Therefore, regulating the level of ROS by adding some redox reagents is a way to adjust protein
expressions. It is reported that the higher oxidative stress could induce excess expression of HO‐1. In the current study, we take advantage of DHA to produce excess of ROS in cancer cells. DHA possesses an endoperoxide bridge structure and the endoperoxide bridge could be broken with free ferrous iron and heme as activators.31,32 The broken endoperoxide bridge of DHA generates oxygen radicals and further increases ROS in cells. We have demonstrated that DHA could increase ROS levels in vitro and if adding extra ferrous iron, the ROS generation was remarkably elevated, indicating that intramolecular endoperoxide bridge of DHA could be activated by ferrous iron to produce the cytotoxic ROS.
In this contribution, we utilized DHA to suppress CDA expression. Specifically, DHA could elevate the ROS levels and HO‐1, a marker of oxidative stress, is increased simultaneously.33 Increased HO‐1 would finally suppress the expression of CDA. In comparison, a ROS scavenger NAC could markedly decrease the ROS level in vitro. As revealed by Frese et al,25 NAC could inhibit HO‐1 expression. GEM is a pyrimidine nucleoside analogue of
deoxycytidine and could be catalyzed by stromal and cellular CDA to dFdU, an inactive metabolite of GEM.10 The decreased CDA expression contributed to the lower production of dFdU. Hence, a series of different combination treatment ratios of DHA and GEM were conducted by MTT assay to investigate distinct interac- tions, ranging from antagonism to synergism. When the molar ratio of DHA and GEM were 10, strong synergism was observed, with CI values 0.7.
Ovarian carcinoma is the leading cause of death from gynecological malignancy.2 A2780, a human ovarian cancer cell lines, were subcutaneously injected into the right flank of Balb/C nude mice to obtain ovarian cancer xenograft tumor model. The DHA + GEM combination treatment group had unexpected antitumor efficiency, the tumors were completely eliminated on day 14.
In summary, we had demonstrated that the DHA could produce cellular ROS generation and the excess ROS could induce cell apoptosis. The obvious cytotoxicity was observed when such extra ferrous ion was added into DHA. The synergistic effect of DHA + GEM in vitro were verified in A2780 cells and we also obtained the optimal molar ratio (DHA/GEM, 10:1, mol/mol). Moreover, the combination treatment group produced markedly more pronounced apoptosis than treatment under DHA or GEM alone. In vivo antitumor efficacy of ovarian cancer A2780, DHA + GEM combination treatment group exhibited excellent antitumor activity and lower systemic toxicity than GEM alone. Noteworthy, the combination treatment group completely eliminated the tumors on day 14.